Many ATLA readers will have heard versions of the story about a tourist driving on a country road in Ireland, who says to an old man leaning over a farm gate, "Can you tell me the way to Tipperary?", only to receive the reply, "No -if I wanted to go to Tipperary, I wouldn't start from here".
What the joke doesn't tell us, of course, is what the driver does next. Does he continue in the same direction, assuming that his reading of the rather small-scale, out-of-date map which he consulted before setting out was more or less correct? And if so, what does he say to the kids on the back seat, who repeatedly say, "Are we there yet?"
Alternatively, does he decide that it would be better to go back to his original departure point and find a more useful map, and plan his journey properly, so that he can be sure that he is heading in the right direction from the outset, confident that he will safely reach his destination in a reasonable time (even if it's much too slow for his impatient passengers).
What those driving the toxicity testing juggernaut seem to be doing is pressing on regardless, in the face of mounting and incontrovertible evidence that the direction in which they are heading is wrong, because the maps they have read and the directions they are taking cannot get them to where they want to be. Why do they do this? The answer is partly because they can get away with it, and partly because going back to base and starting all over again is just too difficult.
The fact is that the animal procedures that are used to comply with regulations, cannot reliably predict what is likely to happen in humans. This is partly because animals and humans are too different, and partly because the doses applied are usually unrealistically high. However, no less important is human variation, which means that there tend to be extremes of susceptibility and resistance around some calculated predicted response. Also, humans don't just sit around exposing themselves to one chemical -they are exposed to a multitude of chemicals in many different ways and in many different situations.
I cannot be an uninvolved, somewhat bemused, observer -like the old man leaning over the gate -but there is a danger that my repeated cries will be somewhat jarring, like those of the kids on the back seat.
All that has to be said, has been said -over and over again -but recognition of the fundamental problems seems to be avoided in many quarters, and animal procedures look like remaining the unreliable foundation on which important decisions about human health and its protection will be made, for many years to come. Just two examples from ATLA will suffice:
First, I have observed with admiration the excellent effort that has gone into the development of the EpiOcular ™ Eye Irritation Test and the Bovine Corneal and Opacity Test, but there seems to be no escape from using rabbit Draize eye test data as the gold standard against which the performance of these alternative methods will be judged. 1, 2 Second, there is the application of the EU REACH system, which has led to two recent progress reports, which are the subject of a Comment in this issue of ATLA. 2 It is, of course, good to see that, up to now, the introduction of the REACH system has not resulted in the enormous increase in animal testing which some had foreseen. However, it is a matter of concern that the registrants have relied on historical animal data, combined with read-across and grouping of chemicals, as well as weight-of-evidence approaches, rather than relying on the use of more-scientific, more-focused non-animal approaches, including in vitro tests and (Q)SAR predictions. The new regulation does not make the data from animal tests any more relevant or any more reliable, and how the new system will lead to a reduction in the risk of harmful effects following human exposure, or to greater protection of the environment (whatever that may mean), remains a mystery to me.
The ultimate problem is that, unlike the modern tourist in Ireland, we don't have sat-nav systems to guide us, and finding the dramatic new methods for hazard identification and risk assessment which are sorely needed, is a daunting challenge confronting all those who are involved in any way.
Regrettably, it looks as if, now obsessed with the REACH system and the Cosmetics Directive, Europe has lost the initiative, and we must look to exciting new developments in the USA -such as the National Institutes of Health grant to a consortium of leading US scientists in the field, for mapping the human toxome 4 -for the breakthroughs which will lead to genuine, sciencebased progress in the years ahead.
